RAL GTPases mediate multiple myeloma cell survival and are activated independently of oncogenic RAS

Area of Science:

• Oncology
• Molecular Biology
• Cancer Signaling

Background:

• Oncogenic RAS mutations are common in multiple myeloma, driving cancer cell survival.
• RAS proteins are historically difficult to target therapeutically.
• RAL, a RAS superfamily GTPase, is a potential mediator of RAS signaling.

Purpose of the Study:

• To investigate the role of RAL in multiple myeloma pathogenesis.
• To determine if RAL is a viable therapeutic target in multiple myeloma.

Main Methods:

• Quantitative analysis of RAL expression in multiple myeloma patient samples.
• RNA interference (RNAi)-mediated knockdown of RAL in myeloma cell lines.
• Assessment of cell death pathways (MAPK, Akt) following RAL abrogation.
• Transcriptome analysis to identify gene expression changes.
• Combination therapy studies with RAL depletion and existing anti-myeloma agents.

Main Results:

• RAL is significantly overexpressed in multiple myeloma compared to normal plasma cells.
• RAL knockdown induces rapid myeloma cell death, partially dependent on Akt signaling.
• RAL activation is independent of RAS mutations and RAS knockdown.
• RAL depletion enhances the efficacy of standard anti-myeloma treatments.
• Distinct gene expression profiles observed after RAS versus RAL knockdown.

Conclusions:

• RAL is a critical driver of multiple myeloma cell survival, operating independently of oncogenic RAS.
• The RAL pathway represents a novel and promising therapeutic target for multiple myeloma treatment.